The European Medicines Agency has validated the Type II Variation marketing authorization application for Enhertu for the treatment of adult patients with HER2 positive unresectable or metastatic solid tumors who have received prior treatment and have no satisfactory alternative treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from three phase 2 trials including DESTINY-PanTumor02, DESTINY-CRC02 and DESTINY-Lung01 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Advertising, drugmaker stocks in spotlight as Trump moves to regulate pharma ads
- Omnicom, WPP under pressure after Trump moves to regulate pharma ads
- Technical Analysis Says These 3 Stocks Are Ready to Rally
- Trump Trade: U.S. President signs new pharma order
- FDA expands approval of AstraZeneca’s Koselugo